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Abstract
Treatment of hypertension-mediated cardiac damage with left ventricular (LV) hypertrophy (LVH) and heart failure remains
challenging. To identify novel targets, we performed comparative transcriptome analysis between genetic models derived
from stroke-prone spontaneously hypertensive rats (SHRSP). Here, we identified carboxypeptidase X 2 (Cpxm2) as a genetic
locus affecting LV mass. Analysis of isolated rat cardiomyocytes and cardiofibroblasts indicated Cpxm2 expression and
intrinsic upregulation in genetic hypertension. Immunostaining indicated that CPXM2 associates with the t-tubule network of
cardiomyocytes. The functional role of Cpxm2 was further investigated in Cpxm2-deficient (KO) and wild-type (WT) mice
exposed to deoxycorticosterone acetate (DOCA). WT and KO animals developed severe and similar systolic hypertension in
response to DOCA. WT mice developed severe LV damage, including increases in LV masses and diameters, impairment of
LV systolic and diastolic function and reduced ejection fraction. These changes were significantly ameliorated or even
normalized (i.e., ejection fraction) in KO-DOCA animals. LV transcriptome analysis showed a molecular cardiac
hypertrophy/remodeling signature in WT but not KO mice with significant upregulation of 1234 transcripts, including
Cpxm2, in response to DOCA. Analysis of endomyocardial biopsies from patients with cardiac hypertrophy indicated
significant upregulation of CPXM2 expression. These data support further translational investigation of CPXM2.
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Hypertension-mediated organ damage (HMOD), including
cardiac hypertrophy, has a major impact on the morbidity
and mortality of hypertensive patients [1, 2]. Thus, sustained
hypertension can result in maladaptive cardiac changes,
including left ventricular (LV) structural remodeling with
LV hypertrophy (LVH) and fibrosis, impaired (diastolic and
systolic) LV function, left atrial enlargement and atrial
fibrillation and, importantly, the development of heart failure
with preserved ejection fraction (HFpEF) or reduced ejection
fraction [2–4]. Approximately half of all patients presenting
with HF have HFpEF [3], and hypertension is particularly
prevalent in this condition [5], for which no established
pharmacological therapies exist beyond blood pressure
control [1, 2].
The development of LVH represents a pivotal early step
in the pathophysiology of progression toward HF [3, 4],
which is modulated by multiple individual and environ-
mental factors, including genetic susceptibility variants that
influence LV mass [6–8]. Animal models, including inbred
hypertensive rat models [9], have proven to be an effective
complementary tool for analyzing cardiovascular disease
mechanisms, including the role of genetic factors in LV
remodeling [10–14]. The stroke-prone spontaneously
hypertensive rat (SHRSP) strain represents such a well-
established inbred hypertension model with an inherited
predisposition to developing HMOD [15, 16]. Regarding
LV remodeling, Fischer (F344) rats are a suitable reference
strain for the analysis of LVH because this strain features a
contrasting phenotype with low LV mass and normal blood
pressure levels [17]. Previous genetic studies in the SHRSP/
F344 model confirmed the presence of a major quantitative
trait locus (QTL) for LV mass on rat chromosome (RNO) 1
(Supplementary Fig. 1) [17]. Building on these previous
findings, we set out to identify potential novel targets for
LVH and LV remodeling in the SHRSP/F344 rat model.
Our data support a functional role of CPXM2 as a novel
candidate for LVH and adverse cardiac remodeling in
hypertension.
Methods
The authors declare that all supporting data are available
within the article and in the Supplementary Material with an
expanded Material and Methods section.
Animal models
All animals were maintained under standard conditions of
regular 12 h diurnal cycles using an automated light
switching device and climate-controlled conditions at a
constant room temperature of 22 °C. Animals had access to
food and water ad libitum. All animal experiments were
approved by the responsible local government committee
and performed in accordance with the guidelines of the
Charité-Universitätsmedizin Berlin and the local authority
for animal protection (Landesamt für Gesundheit und
Soziales, LaGeSo, Berlin, Germany). The registration
numbers are G0354-13, T 0189-02, and O0052/03.
Rats
Male SHRSP and F344 rats were obtained from our colo-
nies at the Forschungseinrichtung für Experimentelle
Medizin (FEM), Charité—Universitätsmedizin, Berlin [17].
To develop the consomic strain SHRSP-1F344 (Rat Genome
Database (RGD)-ID: SHRSP-Chr 1F344/Rkb), we crossed
the SHRSP strain with the F344 strain in accordance with
our linkage results and introgressed the whole rat chromo-
some (RNO)1 from F344 into the SHRSP background as
previously described [17].
Mice
Cpxm2 knock-out (KO) mice were obtained as hetero-
zygous B6;129S5-Cpxm2tm1Lex/Mmucd/rk mice from the
Mutant Mouse Regional Resource Center, University of
California, Davis, USA, and were inbred to produce
homozygous KO (Cpxm2−/−) and wild-type (WT) mice
(Cpxm2+/+). Genotyping of the KO and WT alleles was
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Graphical Abstract
Differential increased cardiac expression of Cpxm2 was assigned to cardiac hypertrophy in SHRSP rats. Cpxm2 knock-out
(KO) in mice reduced cardiac hypertrophy and remodeling in DOCA salt hypertension
performed by PCR (Supplementary Table 1). Only homo-
zygous KO mice and corresponding WT mice were used in
this study.
DOCA-salt hypertension in Cpxm2 KO and WT mice -
in vivo study
Baseline phenotypic characterization of all mice under
control conditions was performed at ~12 weeks of age.
Animals were subsequently followed for 8 weeks under
either deoxycorticosterone acetate (DOCA) DOCA-salt or
SHAM conditions.
DOCA and SHAM experimental groups
At 12 weeks of age, unilateral nephrectomy was performed
under anesthesia (isoflurane 3.5% induction followed by
1.5% maintenance dose) in WT and KO mice (n= 8/group),
and a pellet containing DOCA was implanted in each mouse
subcutaneously (DOCA pellet, 75 mg, 60-day release,
Innovative Research of America, Sarasota, Florida, USA).
Subsequently, these mice were exposed to salt by adding
1% NaCl to drinking water (DOCA groups). Unilateral
nephrectomy was also performed in an additional group of
WT and KO mice (n= 10/group), but these animals
received no DOCA pellet and were given normal drinking
water (SHAM groups). Animals were treated for 8 weeks
overall.
Radiotelemetry
Telemetry devices for continuous blood pressure and
heart rate monitoring (TA11PA-C10, Data Sciences
International, St. Paul, Minnesota, USA) were implanted
in the DOCA mouse groups (WT DOCA n= 8, KO
DOCA n= 8) under isoflurane (isoflurane 3.5% initially
followed by 1.5%) anesthesia when the mice were
10 weeks of age [18]. The catheter was inserted into the
right carotid artery, tunneled subcutaneously and placed
in a subcutaneous pocket along the right flank. After a
recovery period of 10 days, baseline recordings for blood
pressure and heart rate were monitored for 3 days, and
mice were subsequently followed with continuous 24 h
blood pressure and heart rate monitoring for ~8 weeks
under DOCA treatment.
Analysis of cardiac and renal fibrosis and structural
kidney damage
Hearts and kidneys were fixed in formalin (4%), embedded
in paraffin and sectioned into 3 µm slices. Collagen was
stained with picrosirius red for assessment of perivascular
and interstitial fibrosis as reported [19]. The
glomerulosclerosis index and tubulointerstitial damage
index were determined as reported for the analysis of
structural kidney damage [20].
Isolation and analysis of primary cardiac cells
Cardiomyocytes were enzymatically isolated from adult
SHRSP and F344 rats as previously described [21].
Rat primary cardiac fibroblasts were isolated via out-
growth culture as described for murine cardiac fibroblasts
[22], with slight modifications. The outgrowing cardiac
fibroblasts were cultured in Iscove’s medium (Biochrom,
Berlin, Germany) containing 20% fetal calf serum (Bio-
chrom), 100 U/ml penicillin and 100 µg/ml streptomycin
(both PAA, Cölbe, Germany) at 37 °C with 95% air and
5% CO2.
Expression analysis of human endomyocardial
biopsies
Between 2003 and 2012, all patients with suspected cardi-
omyopathy were screened using clinical and endomyo-
cardial biopsy-based diagnostics. The diagnosis of cardiac
hypertrophy was made as recommended by the European
Association of Cardiovascular Imaging and the American
Society of Echocardiography [23]. In all patients, coronary
artery disease and other possible causes of myocardial
dysfunction were excluded by angiography and echo-
cardiography before endomyocardial biopsy. All patients
gave their written informed consent for data storage and
evaluation. The study conformed to the principles outlined
in the Declaration of Helsinki and was approved by the
local institutional review committee of the University Clinic
Benjamin Franklin, Berlin, Germany (approval 225-07).
Patients’ data were anonymized for analyses.
Patients presenting with signs of acute myocarditis with
recent onset of symptoms were excluded, as were those with
proof of intramyocardial enterovirus, adenovirus, human
herpesvirus 6, Epstein–Barr virus, or erythrovirus (B19V)
genomes, as described previously [24]. Other exclusion
criteria were a history of antiviral or immunosuppressive
therapy, clinical or biochemical evidence of concomitant
chronic inflammatory disease, inability to understand the
consent form, or participation or consent to participate in
another study. In addition, 16 patients without signs of
congestive heart failure who underwent coronary angio-
graphy and endomyocardial biopsy to evaluate chest pain
were also enrolled in this study and served as controls.
Endomyocardial biopsies were obtained from the right
ventricular septum. Out of the patients, we selected controls
(n= 16 (38% male), median age 38.5 years, 95% CI
34.8–49.1) without any proven cardiac dysfunction and
patients with hypertrophic cardiomyopathy or hypertrophic
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obstructive cardiomyopathy (n= 20 (75% male), median
age 58 years, 95% CI 49.5–61.6).
Total RNA was isolated from endomyocardial biopsies
during routine biopsy diagnostic analysis using TRIzol
reagent (Life Technologies, Darmstadt, Germany), treated
with DNase (PeqLab, Erlangen, Germany) to remove any
traces of genomic DNA, and reverse-transcribed into cDNA
using a High Capacity Kit (Life Technologies, Darmstadt,
Germany) as described previously [25]. For quantitative
real-time TaqMan PCR, 5 µl gene expression Mastermix
(Thermo Fisher Scientific, USA) and 0.5 µl TaqMan gene
expression assay purchased from Life Technologies;
CDNK1B: Hs00153277_m1; CPXM2: Hs00406866_m1)
were used in a final volume of 10 µl including 1 µl of cDNA
template (the assays were performed in duplicate). Data
were normalized to the CDKN1B mRNA level as an
endogenous control and plotted as mRNA expression using
the 2−ΔCt method [26].
Bioinformatic and statistical analysis
We assessed differences in gene expression between the
three rat strains (SHRSP, F334, and SHRSP-1F334), and in
the genome-wide transcriptome analysis, all samples
except two samples (SHRSP and SHRSP-1F334) passed
quality control and were subsequently analyzed (gene-
level analysis with the R/Bioconductor packages system-
sbio [27] and limma [28]; thresholds for differential
expression: p < 0.05, Benjamini–Hochberg-corrected, and
fold change > log2 (1.5)).
For genome-wide transcriptome analysis of the four
experimental mouse groups (WT SHAM, KO SHAM, WT
DOCA, and KO DOCA), microarray data were analyzed
using TAC-console 4.0 from Affymetrix (parameters:
analysis type “Expression (Gene)”, summarization:
“Gene Level – RMA”, FDR corrected p value with fold
change > 1, meta data loaded from “MoGene_2-0_st”
array type). For mouse data, two outliers were identified
and excluded from the analysis (one WT SHAM and one
KO DOCA sample). Gene ontology (GO) enrichment
analysis was performed on the transcriptome datasets as
reported [29].
If not stated otherwise, data are presented as the means
± SEM. Differences between experimental groups were
analyzed by Student’s t test, Mann–Whitney test, or one-
way ANOVA with post hoc Bonferroni adjustments. A
probability of p < 0.05 was considered to be statistically
significant. We used IBM SPSS Statistics 22 for statistical
analysis, GraphPad Prism and OriginLab 8.1 G for
graph preparation (GraphPad Prism version 8.0 for
Windows, GraphPad Software, La Jolla California USA,
www.graphpad.com; OriginLab Corporation, North-
ampton, MA, USA).
Results
Transcriptome analysis in hypertensive rat models
identifies Cpxm2 as a novel molecule related to LVH
In LV transcriptome analysis, 541 transcripts were differen-
tially expressed between SHRSP and the two reference strains
(Supplementary Tables 2 and 3). To reduce model complexity,
we subsequently focused on mRNAs that were differentially
expressed between the SHRSP and consomic SHSRP-1F344
strains (Fig. 1a and Supplementary Table 3) because both
strains share the same genetic background, while RNO1 car-
ries the LVH QTL. In this analysis, 41 genes with differential
expression were detected, mainly on RNO1 but also on rat
chromosomes 2, 5, 7, 9, 13, 18 and X. Of these, 28 transcripts
were also differentially expressed between the SHRSP and
F344 strains as well as between the SHRSP and consomic
SHSRP-1F344 strains (Fig. 1b and Tables S2 and 3). For further
downstream studies, we selected only positional candidates,
i.e., those transcripts mapping within the LVH QTL on RNO1
between genetic markers D1Rat60 and D1Rat71 (the chro-
mosomal region between nucleotides 186,936,140 and
230,420,772; Fig. S2). Accordingly, six differentially expres-
sed genes were identified, including Bnip3, Slc22a18, Cpxm2,
Eif1ad, Tpcn2, and Pola2 (Fig. 1a, Tables S2 and 3 in bold).
The gene expression of Slc22a18 and Bnip3 was lower in the
SHRSP strain (fold change of 0.9 and 1.9, respectively), while
the expression of Cpxm2 (fold change −0.9), Pola2 (fold
change −0.9), Tpcn2 (fold change −0.8) and Eif1ad (fold
change −0.8) was higher in the SHRSP strain than in the
consomic strain. Slc22a18, Bnip3, Cpxm2, Tpcn2 and Eif1ad
but not Pola2 were also differentially expressed between the
SHRSP and F344 strain. Only Cpxm2 was confirmed in
validation experiments because it demonstrated consistent and
significant differential expression between the SHRSP and
SHSRP-1F344 strains in separate qPCR expression analysis of
LV tissue in adult and young rats at 4 and 8 weeks of age
without established hypertension (Supplementary Fig. 3).
Cpxm2 mRNA expression was significantly upregulated in
LV tissue in the SHRSP strain in comparison to the
F344 strain (at least a 2-fold difference in all age groups). GO
enrichment analysis revealed no significant differential reg-
ulation of GO terms, i.e., biological process terms, between
groups after correction for multiple tests.
Cpxm2 is expressed in both cardiomyocytes and
cardiofibroblasts
Data mining of Cpxm2 (gene ID: 293566 [rat], 55987
[mouse], and 119587 [human]) revealed its original classifi-
cation as a carboxypeptidase, which was only predicted based
on structural analysis [30]. Importantly, subsequent bio-
chemical enzyme activity analysis demonstrated that CPXM2
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lacks—despite its predicted classification—enzymatic car-
boxypeptidase function [30, 31]. Currently, its biological
function remains unclear. We therefore determined the cardiac
cell type(s) in which it is expressed by analyzing primary
cardiomyocytes and cardiofibroblasts isolated and separated
from LV cardiac tissue from the rat model. This analysis
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demonstrated that Cpxm2 mRNA is expressed in both cardi-
omyocytes and cardiofibroblasts (Fig. 1c). In addition, the
upregulation seen in total LV and heart paraffin tissue sections
in the hypertensive model (Fig. 1c, d) was also confirmed for
Cpxm2 mRNA expression in primary isolated cardiomyo-
cytes and cardiofibroblasts obtained from the SHRSP strain
compared to the F344 reference strain (Fig. 1c).
Expression analysis of CPXM2 in rat cardiomyocytes
Confocal fluorescence image analysis of isolated SHRSP rat
cardiomyocytes indicated that CPXM2 was expressed along
the t-tubule network and colocalized with dihydropyridine
receptor (DHPR) (Fig. 2a). This was also confirmed by
immunostaining of paraffin sections of rat hearts (Fig. 2b),
which also indicated expression in the noncardiomyocyte
compartment.
In vivo evaluation of Cpxm2 effect on cardiac
damage in Cpxm2-deficient mice with DOCA-salt
hypertension
Body, heart, and kidney weight
Untreated KO mice did not demonstrate any morphological
or behavioral differences in comparison with WT animals
under normal conditions. In response to DOCA or SHAM
treatment, no significant group differences in body weight
were observed at the end of the observation period (after
8 weeks) (Table 1). Total heart weight was significantly
increased in DOCA-treated mice compared to the corre-
sponding SHAM mice (Table 1). Relative LV weight was
markedly increased in WT DOCA compared to WT SHAM
mice (+95%, Fig. 3a, b, p= 0.000002), and this increase
was significantly lower in the KO DOCA group than in the
KO SHAM group (+46%, Fig. 3a, b, p= 0.01) compared to
the WT group. Relative kidney weights were also increased
in DOCA-treated animals but without group differences
(Table 1).
LV remodeling analysis
Histological analyses of cardiac tissue revealed a significant
increase in LV perivascular and interstitial fibrosis
(Fig. 3c–h) in WT DOCA mice vs. WT SHAM mice (p=
0.01 vs. SHAM groups). The increase in LV perivascular
fibrosis observed in WT DOCA mice was not observed in
KO DOCA mice (Fig. 3c), while LV interstitial fibrosis,
although quantified as lower than that in WT DOCA mice,
was still significantly elevated in KO DOCA mice com-
pared to SHAM mice (Fig. 3f, p= 0.048). Collectively, an
overall significant positive correlation between LV fibrosis
and relative LV weight was found in all groups (perivas-
cular fibrosis r= 0.702, p= 0.000008; interstitial fibrosis r
= 0.513, p= 0.003). However, while further analysis con-
firmed the significant positive correlation between relative
LV weight and perivascular fibrosis (p= 0.0004, Fig. 3e)
and interstitial fibrosis in WT mice (p= 0.04, Fig. 3h), KO
mice exhibited a significant correlation only between rela-
tive LV weight and interstitial fibrosis (p= 0.03, Fig. 3h).
Blood pressure and heart rate
Telemetric analysis in DOCA group animals at baseline,
i.e., before DOCA and salt exposure, revealed no significant
blood pressure difference between WT and KO mice
(Fig. 4a). After uninephrectomy and DOCA implantation
(Day 0), the mean arterial pressure (MAP) increased sig-
nificantly by almost 40 mmHg in both strains (KO p=
0.000004 and WT p= 0.001, Fig. 4a). After 4 weeks, MAP
decreased continuously during the observation period but
did not differ between KO and WT DOCA mice. Heart rate
(HR) was slightly but significantly lower at baseline in KO
animals than in WT animals (−23 bpm at day −2, p=
0.009, Fig. 4a). During the first 4 weeks in which DOCA-
salt-induced hypertension was present, HR increased sig-
nificantly in both strains (KO p= 0.004 and WT p=
0.0004), which showed no significant difference, although
HR remained numerically lower in KO DOCA mice.
Fig. 1 Detection of differential Cpxm2 expression in rats. a Heatmap of
differentially expressed transcripts between 14-week-old male SHRSP (n
= 7), SHRSP-1F344 (n= 7) and F344 (n= 8) rats. Transcripts mapping
within the LVH QTL interval between the genetic markers D1Rat60 and
D1Rat71 are marked with an asterisk. A heatmap was generated using R
3.6.1 (R Core Team, 2019) and gplots were generated (Gregory R.
Warnes, Ben Bolker, Lodewijk Bonebakker, Robert Gentleman, Wolf-
gang Huber, Andy Liaw, Thomas Lumley, Martin Maechler, Arni
Magnusson, Steffen Moeller, Marc Schwartz and Bill Venables (2019))
using the Gplots package (Various R Programming Tools for Plotting
Data, R, package version 3.0.1.1 https://CRAN.R-project.org/package=
gplots). b Venn diagrams displaying the number of differentially
expressed transcripts between the SHRSP and F344 (500 transcripts) and
SHRSP and SHRSP-1F344 (41 transcripts) strains. Common transcripts in
both comparisons are emphasized (n= 28). c Cpxm2 mRNA expression
(diagram) in left ventricular tissue, in primary isolated rat cardiomyo-
cytes, and in primary isolated rat cardiofibroblasts derived from 14-week-
old F344 (white) and SHRSP (black) rats (LV Cpxm2 mRNA, n= 5–8).
Cpxm2 mRNA expression in rat cardiomyocytes and rat cardiofibroblasts
is shown. At least three independent experiments were performed.
Expression levels are displayed as fold changes of Cpxm2 expression
compared to the expression in the F344 strain ± SEM. The rat mRNA
expression of Cpxm2 was normalized against Hprt expression. d Paraffin
sections of hearts from the SHRSP (right section) and F344 (left section)
strains were analyzed with immunofluorescent staining of CPXM2 (red,
cy3), the cardiomyocyte cell wall (green, WGA Alexa488) and nuclei
(blue, DAPI) (magnification ×40; scale bar: 50 µM). The corresponding
whole LV sections are shown in Supplementary Fig. 9. Comparison of
CPXM2 staining between the SHRSP and F344 strains indicated higher
expression in the SHRSP strain. Statistical analyses were performed using
Student’s t test in the rat experiments (*p < 0.05 vs. the F344 strain)
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Subsequently, between weeks 4 and 8 of DOCA exposure,
between Days 33 and 43, HR was significantly lower in KO
DOCA mice than in WT DOCA mice (Day 33 p= 0.045,
Day 34 p= 0.045, Day 36 p= 0.048, Day 39 p= 0.048,
Day 40 p= 0.048, Day 41 p= 0.016, Day 42 p= 0.016,
Day 43 p= 0.028; Fig. 4a).
LV functional analysis
Echocardiography time course analysis demonstrated a
significant and progressive enlargement of end-systolic
(after 8 weeks+ 69%, p= 0.0000006) and end-diastolic
(after 8 weeks + 40%, p= 0.00001) LV internal diameters
in DOCA-treated WT mice compared to SHAM WT mice
(Fig. 4b). This LV enlargement was significantly attenuated
in DOCA KO mice (end-systolic LV internal diameter p=
0.002 and end-diastolic LV internal diameter p= 0.04 vs.
DOCA WT mice, respectively). WT DOCA mice showed
significantly reduced LV ejection fraction (EF) after 4 and
8 weeks of DOCA treatment compared to WT SHAM mice
(Fig. 4c, after 4 weeks p= 0.00003 and after 8 weeks p=
0.00001, respectively). This decline in EF was significantly
attenuated in DOCA-treated KO mice (p= 0.01 vs. DOCA
WT mice). Of interest, at 8 weeks of DOCA treatment, LV
internal systolic diameter and EF were not significantly
different between the DOCA KO groups and SHAM groups
(Fig. 4b, c). Similarly, fractional shortening (FS) was sig-
nificantly reduced in WT DOCA mice (after 4 weeks p=
0.000005 and after 8 weeks p= 0.00003, Table 1) but not in
KO DOCA mice compared to the corresponding SHAM
mice (Table 1).
Hemodynamic characterization at the end of the observa-
tion period by LV pressure-volume catheter analysis revealed
that LV end-systolic volume (LVESV, +600%, p=
0.0000000001) and end-diastolic volume (LVEDV,+ 146%,
p= 0.00000004) were significantly elevated in the WT
DOCA group compared with the SHAM group, in agreement
with the echocardiography data. LVESV and LVEDV were
Fig. 2 Cardiac fluorescence
imaging analysis in rats. a
Freshly isolated rat
cardiomyocytes were analyzed
using Z stack confocal
fluorescence imaging.
Cardiomyocytes were stained
for CPXM2 (FITC, green) and
L-type Ca2+ channel
dihydropyridine receptor
(DHPR) (Alexa 594, red), and
corresponding overlays were





as described previously [63].
Image analysis after
CPXM2 staining indicated
expression along t-tubules but
not in intercalated disks (Z-line),
which was confirmed by
corresponding DHPR staining. b
Paraffin sections of SHRSP rats
were analyzed for colocalization
of CPXM2 (red arrow) and
DHRP (green arrow).
Colocalization is marked with
yellow arrows. Scale bar: 5 µM
Cpxm2 as a novel candidate for cardiac hypertrophy and failure in hypertension
significantly lower (−61% and −51%) in KO DOCA mice
than in WT DOCA mice (LVESV p= 0.0000001 and
LVEDV p= 0.00006, respectively). LV end-diastolic pres-
sure (LVEDP) was significantly elevated in WT DOCA but
not in KO DOCA mice compared to SHAM mice (p= 0.02,
Fig. 4d). In addition, both systolic (+dP/dt) and diastolic
(−dP/dt) LV function were significantly impaired (p= 0.04
and p= 0.01, respectively) in WT DOCA but not in KO
DOCA mice compared to SHAM mice (Fig. 4d).
When we analyzed the correlation between individual
Cpxm2 mRNA expression and cardiac phenotypes in WT
mice following DOCA treatment, a nonsignificant (possible
due to the limited sample size) negative trend for correlation
between the Cpxm2 mRNA level and relative LV weight (r
=−0.872, p= 0.054) and the Nppa mRNA expression
level (r=−0.381, p= 0.527) was observed, while the
correlation with LV EF was blunted (r=−0.003, p=
0.996) due to the low level of variation of this phenotype in
all WT DOCA mice (Supplementary Fig. 4).
Renal damage analysis
Analysis of structural glomerular and tubulointerstitial
damage indices revealed a significant increase in both
DOCA groups but no significant difference between WT
and KO mice (Supplementary Fig. 5b, c). Renal interstitial
fibrosis was also numerically higher in both DOCA
groups, although this increase in KO DOCA compared
with KO SHAM mice was not significant (Supplementary
Fig. 5a).
Cardiac transcriptome analysis
Under SHAM conditions, no significant differences in LV
transcriptome analysis data were observed between WT and
KO mice. In contrast, 1243 transcripts were differentially
expressed between WT SHAM and WT DOCA mice (Fig. 5
and Supplementary Table 4); a typical cardiac hypertrophy
and remodeling expression pattern, e.g., significant upre-
gulation of actin alpha 1 (Acta 1, −4.8-fold change), Nppa
(−3.2-fold change), and periostin (Postn −7.9-fold change),
was observed in DOCA-treated WT mice (Supplementary
Table 4). Of interest, there were no differentially expressed
transcripts between the KO SHAM and KO DOCA mice in
the transcriptome analysis, underlining the impact of
Cpxm2 on cardiac remodeling. In the separate qPCR ana-
lysis, we confirmed the significantly increased mRNA
expression of natriuretic peptide A (Nppa) in WT DOCA
compared to WT SHAM mice (FDR p= 0.0000003, Sup-
plementary Fig. 5), while no significant increase was seen in
KO DOCA compared to KO SHAM mice (FDR p= 0.79,
Supplementary Fig. 6). However, Nppa mRNA expression
was also significantly higher in WT DOCA than in KO
DOCA mice (p < 0.05, Supplementary Fig. 6) in the tar-
geted separate mRNA expression analysis by qPCR. Inter-
estingly, Cpxm2 was one of the most differentially
Table 1 Characteristics of WT SHAM, WT DOCA, KO SHAM and KO DOCA animals after 8 weeks of DOCA treatment
Phenotype Strain SHAM DOCA p-value (ANOVA)








BW (g) WT 31.62 ± 0.99 29.19 ± 0.94 0.040 0.387 0.237 1.000 1.000
KO 32.70 ± 0.54 30.24 ± 0.63
HW (mg) WT 125.40 ± 3.63 225.38 ± 23.31 0.000001 0.000006 0.014 1.000 0.011
KO 118.06 ± 2.41 166.30 ± 16.58
KW (mg) WT 222.90 ± 7.03 277.80 ± 15.30 0.00002 0.044 0.00006 1.000 0.643
KO 220.30 ± 5.62 311.50 ± 22.60
KW/TL (mg/mm) WT 12.31 ± 0.36 15.52 ± 0.85 0.00003 0.037 0.0001 1.000 1.000
KO 12.05 ± 0.35 17.08 ± 1.32
SV (µl) WT 28.78 ± 1.46 31.67 ± 4.72 0.198 1.000 0.359 1.000 1.000
KO 28.83 ± 1.86 35.72 ± 3.35
CO (ml/min) WT 13.33 ± 0.86 14.10 ± 2.32 0.598 1.000 1.000 1.000 1.000
KO 12.29 ± 1.03 14.62 ± 1.54
FS (%) WT 28.10 ± 1.77 12.47 ± 1.01 0.00008 0.00003 1.000 0.391 0.005
KO 23.74 ± 1.31 23.58 ± 2.52
Phenotype values are means ± SEM. Significant p-values are presented in bold
BW body weight, HW heart weight, KW kidney weight, TL tibia length, SV stroke volume, CO cardiac output, FS fractional shortening, WT wild
type, KO knock-out, SHAM SHAM-operated, DOCA Desoxycorticosterone acetate-treated
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Fig. 3 Cardiac structural and molecular characteristics of Cpxm2 wild-
type (WT) and knock-out (KO) mice under SHAM and DOCA con-
ditions. The left ventricular (LV) weight and LV fibrosis rate as well as
genetic expression profile in WT (white) and KO (black) after 8 weeks
of SHAM or DOCA treatment, n= 3–10. a Mean relative left ven-
tricular weight [LVW/tibia length (TL)]. b Example whole hearts. c–e
Mean perivascular fibrosis was analyzed after picrosirius red staining
in three fields of view per animal; representative photographs are
shown (d). Mean perivascular fibrosis was plotted against relative LV
weight for Cpxm2 WT (r= 0.857, p= 0.00004, e) and Cpxm2 KO
mice (r= 0.417, p= 0.096, e). f–h Mean interstitial fibrosis was
analyzed after picrosirius red staining in three fields of view per ani-
mal; representative photographs are shown (g). Mean interstitial
fibrosis was plotted against relative LV weight for Cpxm2 WT (r=
0.531, p= 0.04, h) and Cpxm2 KO (r= 0.525, p= 0.03, h). Statistical
analyses were performed using one-way ANOVA with the Bonferroni
post hoc test, *p < 0.05 vs. all other groups, **p < 0.05 vs. SHAM
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expressed transcripts between the two WT groups (fold
change −4.9, FDR p= 0.02, Supplementary Table 4) and
was upregulated in DOCA-treated WT mice; the latter
finding was confirmed in separate qPCR analysis, while KO
mice showed no LV Cpxm2 mRNA expression (Supple-
mentary Fig. 7). In the direct comparison between WT
DOCA and KO DOCA mice, only one transcript, encoding
the gene Zdhhc2, was significantly upregulated after cor-
rection for multiple tests (−2.71-fold change, FDR p=
0.04) in WT DOCA mice. This transcript was also sig-
nificantly upregulated in WT DOCA mice compared to WT
SHAM mice (−3.12-fold change, FDR p= 0.005). GO
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enrichment analysis indicated a significant association of
GO terms with the response to DOCA in WT mice but not
in KO mice, including the terms response to hypoxia, fatty
acid beta-oxidation, heart development, cell adhesion, and
response to mechanical stimulus (FDR p < 0.03).
CPXM2 expression is upregulated in patients with cardiac
hypertrophy
We performed explorative analysis of CPXM2 mRNA
expression in samples isolated from endomyocardial biop-
sies of human patients with cardiac hypertrophy and con-
trols. CPXM2 mRNA expression was significantly higher in
patients with cardiac hypertrophy (n= 20) than in patients
without cardiac hypertrophy (n= 16, p= 0.0054, Fig. 6).
Discussion
In this study, we first performed comparative transcriptome
analysis of LV tissues of rat models of hypertension, which
mapped a novel candidate, i.e., Cpxm2, to a previously
identified QTL for LV mass [17]. In subsequent validation
experiments, we confirmed the expression and upregulation
of Cpxm2 in primary cardiac fibroblasts, cardiomyocytes
and total LV tissue in SHRSP rats.
The similar (in vivo) upregulation of Cpxm2 in the hearts
of young animals at 4 weeks of age and before the devel-
opment of sustained hypertension and in (in vitro) isolated
cardiomyocytes and cardiofibroblasts corroborated a poten-
tial intrinsic role of Cpxm2 in LV remodeling in hyperten-
sion. In aging SHRSP rats, there was a subsequent further
pronounced increase in Cpxm2 expression, which paralleled
the reported increase in blood pressure in this strain
(Fig. S3), suggesting additional upregulation in response to
pressure overload. Nevertheless, other systemic effects, e.g.,
neurohumoral activation and cardiac infiltration of inflam-
matory cells, could also contribute to the further increase in
Cpxm2 expression in the SHRSP strain. In a previous study,
we clearly demonstrated that LV tissue levels of angiotensin
II were not elevated in the SHRSP strain that we used in the
current work [32]. Consequently, it appears that the upre-
gulation of Cpxm2 expression in the SHRSP strain is not
primarily induced by angiotensin II. This notion does not,
however, exclude the possibility that inhibition of angio-
tensin II or aldosterone signaling with respective drug
treatments can prevent the induction of Cpxm2 expression in
the heart. Such strategies could be explored in future studies.
Our subsequent studies in Cpxm2-deficient mice demon-
strated a significant impact on maladaptive remodeling and
heart failure development in DOCA-salt hypertension.
DOCA-treated Cpxm2 KO mice showed attenuated LV
dysfunction and enlargement as well as decreased LV
fibrosis compared with DOCA-treated Cpxm2-WT mice
[33]. In contrast, Cpxm2 deficiency had no protective effect
on structural tissue damage in the kidney. The development
of hypertension (mild to severe) and cardiac remodeling
(diastolic to systolic dysfunction) in response to DOCA
exposure may vary depending on the DOCA dose and time
course of exposure, differences between species and strains,
and combination with unilateral nephrectomy and increased
dietary salt intake [34–37]. The DOCA protocol used in the
current study in mice clearly induced severe hypertension
and resulted in marked increases in LV masses and dia-
meters as well as impairment of both diastolic and systolic
LV function in WT mice. The lack of Cpxm2 in KO mice
significantly ameliorated this phenotype.
In the comparison between WT and KO mice, a sig-
nificant, albeit modest, lower HR was noted at baseline in
KO animals. This difference and the subsequent trend of a
lower HR in Cpxm2-deficient mice might have contributed
to the protective cardiac effect in response to DOCA. The
lower HR in KO animals could be attributable either to
intrinsic cardiac effects of Cpxm2 deficiency or to systemic
effects, possibly related to the ability of the autonomic
nervous system to control heart rate, in the general KO
model. Future studies of conditional KO models could help
dissect these effects; however, such studies would require
targeting both cardiomyocytes and cardiofibroblasts based
on the observed cardiac expression of Cpxm2.
Importantly, transcriptome analysis demonstrated a pro-
found impact of Cpxm2 KO on the LV transcriptome in
response to DOCA hypertension. Hence, the induction of a
characteristic LVH/remodeling transcriptome signature with
a number of significant changes in response to DOCA in
Fig. 4 Cardiac function characteristics of Cpxm2 wild-type (WT) and
knock-out (KO) mice under SHAM and DOCA conditions. a Mean
arterial blood pressure (MAP) and heart rate (HR) in the DOCA mouse
model. MAP (bottom) and HR (top) in WT (white, n= 4–7) and KO
(black, n= 7–8) mice before DOCA pellet implantation and unilateral
nephrectomy (baseline, Days −3 to −1) and after DOCA pellet
implantation and unilateral nephrectomy (DOCA treatment, Day 12 to
Day 53). MAP and HR are displayed as the mean ± SEM; statistical
analyses were performed using the Mann–Whitney test, *p < 0.05 vs.
WT DOCA (Days −2, 13, 33, 34, 36, and 39–43). b, c Left ventricular
(LV) function according to echocardiographic analysis of WT (white)
and KO (black) mice under SHAM and DOCA conditions after
baseline (before DOCA pellet implantation and unilateral nephrect-
omy), after 4 weeks of DOCA treatment and after 8 weeks of DOCA
treatment; n= 5–10. Mean LV diameter at systole (b, left diagram)
and diastole (b, right diagram) and mean LV ejection fraction (EF, c)
are displayed. d LV function according to hemodynamic analysis of
WT (white) and KO (black) mice after 8 weeks of SHAM or DOCA
treatment, n= 5–10. The mean LV end-diastolic pressure (left dia-
gram) and mean maximum and minimum values of the pressure
derivative during a loop (dP/dt, right diagram) are displayed. Statistical
analyses were performed using Student’s t test for the baseline data
and one-way ANOVA with the Bonferroni post hoc test for data from
4 weeks and 8 weeks, *p < 0.05 vs. all other groups at the same time
point, **p < 0.05 vs. the corresponding SHAM group
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WT mice was abolished overall in Cpxm2-deficient DOCA
mice. This result is in line with the moderate structural and
functional cardiac remodeling phenotypes observed in the
KO DOCA mice. However, a limitation of our microarray
analysis is the limited sample size, which may have resulted
in low statistical power for detecting differentially expres-
sed genes (Supplementary Fig. 8).
Of interest, Cpxm2 mRNA expression was also sig-
nificantly upregulated in LV tissue of WT DOCA mice
compared to control WT mice.
Our expression analysis of CPXM2 in endomyocardial
biopsies of patients confirmed not only the expression of
CPXM2 in the human heart but also significant CPXM2
upregulation in patients with various forms of cardiac
hypertrophy. Our analysis of Cpxm2 expression in biopsies
of patients should be considered explorative and for the
purpose of generating hypotheses. Notwithstanding these
limitations, it is important to confirm the expression of
Cpxm2 in the human heart and to provide preliminary
support for the differential regulation of CPXM2 in human
heart diseases, which would provide a rationale for further
clinical studies.
Carboxypeptidases by definition are enzymes with cata-
lytic activity that remove protein C-terminal amino acids;
they show diverse tissue distribution and biological func-
tions [38, 39]. However, at least three members of the
carboxypeptidase N/E subfamily lack catalytic function
[31]: (i) carboxypeptidase × member 1 (CPXM1, CPX1,
CPXM); (ii) carboxypeptidase × member 2 (CPXM2,
CPX2); (iii) and aortic carboxypeptidase-like protein/
Fig. 6 Detection of differential Cpxm2 expression in humans.CPXM2
mRNA expression in control patients without cardiac hypertrophy (n
= 16) and in patients with cardiac hypertrophy (n= 20). The human
mRNA expression of CPXM2 was normalized against CDKN1B
expression. Statistical analyses were performed using the
Mann–Whitney test in human samples, **p < 0.01 vs. control
Fig. 5 Cardiac molecular
characteristics of Cpxm2 wild-
type (WT) and knock-out (KO)
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adipocyte enhancer binding protein 1 (ACLP, alias AE
binding protein AEBP1). Thus, it is important to emphasize
that CPXM2 also lacks enzymatic carboxypeptidase func-
tion for typical substrates [30, 31]. Currently, its biological
function remains unclear. Moreover, the presence and
potential function of CPXM2 in the circulation remain to be
determined. CPXM1 was demonstrated to be involved in
adipogenesis, osteoclastogenesis, and cancer [40–42]. Ear-
lier studies showed AEBP1 to have a functional role in
fibroblast organization and transition, wound healing, and
neuromuscular development [43, 44]. More recently,
AEBP1 was identified as a candidate gene in Ehlers-Danlos
syndrome [45]. Previous studies have indicated a role of
Cpxm2 in oncogenesis and development, as well as in
disorders [46–50]. Interestingly, a mouse model with caloric
restriction demonstrated reduced Cpxm2 expression in
whole hearts [51]. These three proteins all contain an
N-terminal domain with homology to the discoidin domain,
i.e., discoidin 1, whereas none of the other members in the
metallocarboxypeptidase family contain such a domain
[31]. Thus, the potential interacting structure of Cpxm2 may
lie in its discoidin or factor 5/8 type C domain [52]. These
domains can bind to lipids, glycans, heparin-like molecules
and proteins (reviewed in [52]). Proteins containing dis-
coidin domains have been found to be related to cellular
adhesion, migration, and aggregation events. These rela-
tionships could be associated with extracellular matrix
function and thus influence cardiac remodeling [53–55].
The expression of CPXM2 in cardiofibroblasts appears to
be in agreement with existing knowledge of discoidin
domain-containing proteins and their role in extracellular
remodeling. In contrast, the expression of CPXM2 in car-
diomyocytes and its potential relevance are currently
unclear. Nevertheless, GO enrichment analysis of the tran-
scriptome dataset comparing the response to DOCA of the
WT and KO mice indicated a significant association with
the GO terms response to hypoxia, fatty acid beta-oxidation,
heart development, cell adhesion, and response to
mechanical stimulus. These biological processes are linked
to cardiac function, cardiac remodeling and cardiac failure,
and their associations thereby substantiate a putative role of
CPXM2 in cardiac failure. Furthermore, our immunostain-
ing analysis revealed that expression of CPXM2 in cardi-
omyocytes was associated with the t-tubule network and
colocalized with DHPR. Of interest, a recent systematic
analysis of the proteome of cardiac t-tubules indicated that a
few proteins (1.8%) of all extracellular (matrisome) proteins
of the heart had a tubule-staining immunohistochemistry
pattern [56]. In this regard, Cpxm2 may represent a novel
member of this small group of proteins that maintain the
structure and function of t-tubules by being expressed
in both compartments [56, 57]. Cpxm2 could link
mechanical signals that act on the extracellular matrix and
cardiomyocyte cell membranes of the t-tubule network and
may play an important role in cardiac tissue remodeling in
hypertension, as recently reviewed by Saucerman et al. [57].
The identified localization of the Cpxm2 protein at
t-tubules indicates its potential role in the homeostatic
function of the t-tubule structure or calcium handling, which
should be investigated in future functional studies on
calcium-handling proteins. Although limited in sample size,
our microarray transcriptome analysis revealed no sig-
nificant differences in mRNA expression levels between
WT and Cpxm2-deficient mice during SHAM conditions
for genes involved in calcium handling, including Atp2a2
(SR Ca2+ -ATPase [(SERCA2], Cav3 (cavelolin 3), Ncx
(sodium/calcium exchanger), Ryr2 (ryanodine receptor 2),
Pln (phosholamban) and Sln (sarcolipin).
Our LV transcriptome analysis in the mouse model
indicated that only Zdhhc2 was differentially expressed
between WT DOCA and KO DOCA mice after correction
for multiple tests, while for example, Nppa mRNA also
showed significantly higher levels in WT DOCA mice in
the separate targeted analysis comparing WT DOCA and
KO DOCA mice using qPCR. This result points to a
potential link between Cpxm2 and the enzymes of the zinc-
finger aspartate-histidine-histidine-cysteine family (zDHHC
enzymes). These enzymes mediate S-acylation (palmitoy-
lation) and are thus important in posttranslational mod-
ification [58]. Enzymatic S-acylation regulates the
localization and function of different intracellular and
membrane proteins [58], including cardiac ion channels and
transporters, e.g., Nav1.5 [59]. The impact of altered pal-
mitoylation of NAV1.5 on cardiac excitability was pre-
viously demonstrated in vitro [59]. However, thus far only
Carboxypeptidase D, a carboxypeptidase with enzymatic
function, was identified as a substrate of S-palmitoylation,
and this S-palmitoylation impacts its cellular localization
and half-life [60]. Further studies are thus necessary to
clarify the potential interaction of Cpxm2 and Zdhhc2.
Another limitation of our study is related to the fact that
for the definitive confirmation of a causative effect of
Cpxm2 on the development of LVH in SHRSP rats, tar-
geted knock-out of this gene in SHRSP rats is warranted
[61]. Moreover, experiments in transgenic animals over-
expressing Cpxm2 in the heart could also provide additional
important information.
In summary, novel proteins that are expressed in the left
ventricle of the heart and contribute to the transition from
LVH to heart failure are of interest for the prevention and
treatment of heart failure [62]. Cpxm2 represents such a
novel target, as it is upregulated in genetically hypertensive
rat models, in response to DOCA-salt hypertension in mice,
and in human patients with cardiac hypertrophy. Cpxm2
deficiency in mice with sustained hypertension results in
profound protection against cardiac damage and failure.
Cpxm2 as a novel candidate for cardiac hypertrophy and failure in hypertension
Although CPXM2 lacks enzymatic function and its mole-
cular function is currently unclear, its expression and
upregulation in both cardiomyocytes and cardiofibroblasts
appears to be important. Moreover, its assignment to the
small group of proteins that are expressed in both the
matrisome and the t-tubule network of cardiomyocytes
suggests that CPXM2 could play a role at this unique
interface and possibly be involved in mechanosensitive
pathways in the heart.
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